Parsabiv 5 mg solution for injection, Parsabiv 10 mg solution for injection
20170724
Phase 3 small_molecule active
Quick answer
Parsabiv 5 mg solution for injection, Parsabiv 10 mg solution for injection for Secondary hyperparathyroidism (SHPT) in pediatric patients with chronic kidney disease (CKD) in hemodialysis is a Phase 3 program (small_molecule) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen Technology (Ireland) UC
- Indication
- Secondary hyperparathyroidism (SHPT) in pediatric patients with chronic kidney disease (CKD) in hemodialysis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active